Evotec and PsychoGenics Enter into a Strategic Alliance to Provide Integrated CNS Drug Discovery Solutions

Wednesday, 25. May 2011 07:29
Evotec AG /
Evotec and PsychoGenics Enter into a Strategic Alliance to Provide Integrated
CNS Drug Discovery Solutions
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - 25 May 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has entered into a strategic alliance with
PsychoGenics Inc. to provide integrated CNS drug discovery solutions to
pharmaceutical and biotech companies. The two companies will work together in a
seamless fashion to provide existing and new clients access to their
complementary drug discovery platforms for the identification and development of
new therapeutics to treat CNS disorders.

 Evotec is the premier provider of drug discovery alliances to the
pharmaceutical industry based on its state-of-the-art technology platform and
broad range of integrated capabilities.  Evotec has therapeutic area expertise
in metabolic disease, CNS, pain, inflammation and oncology and differentiates
itself based on a strong track record in drug discovery, scientists with many
years experience in the industry and an innovative technology platform.

PsychoGenics is a leader in preclinical neurobiology applied to CNS and pain
drug discovery and development. Its extensive capabilities coupled with its
proprietary, high-throughput behavioral testing platforms that employ cutting
edge bioinformatics allows the rapid screening and optimization of compounds for
CNS activity. These proprietary platforms are used for the characterization of
drugs, the phenotyping of disease models and the multi-dimensional testing of
drugs in disease models.

Dr Mario Polywka, Chief Operating Officer at Evotec stated: "By bringing
together the industry leading CNS drug discovery platforms of Evotec and
PsychoGenics, our clients and partners will benefit through an increased
probability of success and faster and more informed decision making in their
drug discovery efforts with the goal of delivering pre-clinical candidates in
the most time and cost efficient manner."

Dr Emer Leahy, President and CEO of PsychoGenics explained: "We are delighted to
enter into this collaboration with Evotec, an innovative leader in drug
discovery. PsychoGenics and Evotec each have a long-standing history of
successful partnerships in which they share discovery risk with pharmaceutical
companies, and have delivered several pre-clinical candidates. Now, by combining
forces, partners have the opportunity to avail themselves of fully-integrated
and proprietary capabilities to drive and transform their CNS discovery programs
and lower their overall risk."

No financial details are disclosed.

Contact Evotec AG:

Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler@evotec.com


Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions or
circumstances on which any such statement is based.


--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Pdf of Press Release:
http://hugin.info/131215/R/1518536/455034.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1518536]
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.